To read the full story, subscribe or sign in.

NeurogesX Reports Positive Phase III Study Of NGX-4010

Sep. 5, 2007

NeurogesX Inc. reported the pain patch NGX-4010 met primary and secondary endpoints in a third Phase III trial, and the second in patients with postherpetic neuralgia. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Nov. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 12, 2025.

Could restricting diversity efforts stall women’s health research?

BioWorld

Recent progress in redressing the historical underfunding and neglect of women’s health could be undermined by the backlash against diversity, equity and...

Alkermes’ alixorexton hits endpoints in narcolepsy phase II

BioWorld

Alkermes plc’s placebo-controlled phase II study of alixorexton in treating narcolepsy type 2 (NT2) hit its dual primary endpoints, producing statistically...

Pazdur ‘optimal fit’ to lead FDA’s CDER

BioWorld

In reaching within to name 26-year FDA veteran Richard Pazdur as the next CDER director, FDA Commissioner Marty Makary likely chose the best possible person to...